AbbVie Submits IPO Prospectus for ABBV-CLS-484, a First-in-Class Oral PTPN2/PTPN1 Inhibitor Targeting Undruggable Phosphatase for Cancer Immunotherapy

In 2017, scientists from Harvard Medical School and the Dana-Farber Cancer Center identified PTPN2 as a new target for cancer immunotherapy through an in vivo CRISPR screen. Chemists at AbbVie discovered ABBV-CLC-484, an orally available PTPN2/PTPN1 active site inhibitor, with an EC50 of 0.176 μM at the cellular level. In vitro studies have shown that AC484 can enhance the sensitivity of tumor cells to IFNγ and promote the activation and function of T cells.